MedPath

Intrathecal Morphine for Analgesia in Video-assisted Thoracic Surgery

Phase 4
Recruiting
Conditions
Pain, Postoperative
Interventions
Registration Number
NCT05351229
Lead Sponsor
University of Chicago
Brief Summary

VATS is widely used for diagnosis and treatment of intrathoracic conditions. Despite many benefits, postoperative pain continues to be intense after VATS. The optimal strategy for pain management has not been defined. In this randomized, placebo-controlled, double-blinded clinical investigation, investigators hypothesize that 5 mcg/kg intrathecal morphine will decrease postoperative analgesic consumption and reduce pain.

Detailed Description

This is a randomized, placebo-controlled, double-blinded clinical trial. Patients will be randomized into one of two groups. Group A (Placebo, control group) will receive intrathecal sterile normal saline and Group B (Morphine group) will receive 5mcg/kg preservative free intrathecal morphine.

American Pain Society Outcome Questionnaire (APS-POQ) will be administered to patients prior to discharge (see data sheet).

Patients will be followed up with a phone survey at 1 and 3 months after surgery to assess the presence, nature, and severity of chronic persistent surgical pain. The Brief Pain Inventory is a reliable and valid measures of the interference of pain with physical functioning and will be used. Additionally patients will be asked about use of pain medications

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
90
Inclusion Criteria
  • Age 18-80 years old
  • Undergoing elective video-assisted thoracoscopic surgery for anatomical lung resection
  • General anesthesia with anticipated intraoperative extubation.
Exclusion Criteria
  • American Society of Anesthesiologists (ASA) classification of 4 or 5
  • Anticipated postoperative intubation
  • Significant liver disease
  • Preoperative use of intravenous inotropes and/or vasopressor support
  • Preoperative mechanical ventilation
  • Preoperative use of mechanical circulatory support device (intraaortic balloon pump, ventricular assist device, extracorporeal membrane oxygenation)
  • Severe pulmonary disease (home oxygen requirement and/or current oral steroid use)
  • Morphine allergy
  • Opioid or alcohol abuse
  • Chronic pain
  • Renal failure
  • Inability to comprehend English language
  • Bleeding disorder
  • Abnormal preoperative coagulation
  • Infection
  • Patient refusal

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlaceboPlacebo, Intrathecal saline
MorphineMorphine SulfateIntrathecal morphine
Primary Outcome Measures
NameTimeMethod
Postoperative morphine equivalent consumption24 hours after surgery

Total MG of analgesic medications given converted to morphine

Secondary Outcome Measures
NameTimeMethod
self-reported limitation of daily activity at 1 and 3 months1 month and 3 months after surgery

Questions asked via phone call at 1 month and 3 months

pain qualities1 month and 3 months after surgery

pain intensity, location, quality via Brief Pain Inventory

Self-reported patient satisfactionprior to discharge from hospital, likely 1-3 days after surgery

American Pain Society Outcome Questionnaire

Self reported use of analgesic medications1 month and 3 months after surgery

Questions asked via phone call at 1 month and 3 months.

Number of pain interventionsup to 48 hours postoperative

Number of times patient given medication for pain

Postoperative opioid related side effectsup to 48 hours postoperative

Nausea medication administration, airway events, urinary retention, pruritus medication given,

Postoperative painUp to 48 hours postoperative

Visual analog score between 0-10

Trial Locations

Locations (1)

University of Chicago

🇺🇸

Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath